The U.S. Food and Drug Administration (FDA) today announced the membership of the Pharmacy Compounding Advisory Committee. The committee is comprised of 14 members – 12 voting and 2 non-voting – who will provide advice on scientific, technical and medical issues concerning drug compounding under sections 503A and 503Bof the Federal Food, Drug, and Cosmetic Act (Chapter V, Drugs & Devices), and make appropriate recommendations to the Commissioner of Food and Drugs.
Among the 12 voting members of the new advisory committee is Tennessee pharmacist William A. Humphrey, BSPharm, MBA, MS, Director of Pharmacy Operations at St. Jude Children’s Research Hospital in Memphis. A member of the Tennessee Pharmacists Association and the Tennessee Society of Health-System Pharmacists, Dr. Humphrey is recognized on the committee for his expertise in Clinical Pharmacy. All committee members are experts in pharmaceutical compounding and manufacturing, pharmacy, medicine, or pharmaceutical regulation.
The committee includes voting members representing the United States Pharmacopeia (USP), a nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines manufactured, distributed and consumed worldwide; the National Association of Boards of Pharmacy (NABP), a professional organization that supports the state boards of pharmacy in protecting public health; and one member identified with consumer interests. The two non-voting members represent the pharmacy compounding industry and the pharmaceutical manufacturing industry.
“Advisory committees are a very important source of knowledge and advice for drug regulation,” said Janet Woodcock, MD, Director of the FDA’s Center for Drug Evaluation and Research. “This is a key step toward implementing the compounding provisions of the Drug Quality and Security Act, and I expect we will benefit greatly from the advice and recommendations the members of the committee provide.”
Click here to view the original press release.